by RNA therapeutics is an innovative approach for treating diseases through modulation of gene expression via RNA interference (RNAi) or RNA activation. Strategies such as small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, and aptamers are used to silence disease-causing genes or modulate gene expression. These therapeutics hold potential for developing treatments across various disease areas including cancer, cardiovascular disorders, infectious diseases, genetic disorders, and more.
The RNA Therapeutics Market is estimated to be valued at US$ 2.5 Mn in 2024 and is expected to exhibit a CAGR of 68% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the RNA therapeutics are Alphavax, Arcturus Therapeutics, Atyr Pharma, Gritstone Bio, HDT Bio and Among Others. These players are involved in developing novel RNA therapeutics for various disease conditions.
The RNA Therapeutics Market offers lucrative opportunities owing to the rising prevalence of rare diseases and cancers. Development of personalized RNA medicines also presents opportunities for market players. Further, innovation in RNA delivery technologies is expected to drive the demand.
With strong presence across North America and Europe, leading players are expanding their reach in high growth markets of Asia Pacific and Latin America. Partnerships with clinical research organizations and funding from private and public sources are fueling global expansion plans of RNA therapeutic companies.
Market Drivers
The key driver which is contributing to the growth of the RNA therapeutics market is the high incidence of rare diseases globally. According to some estimates, over 300 million people are affected by around 7,000 known rare diseases. However, majority rare diseases still lack effective treatment options. RNA therapeutics hold promise to address several rare disorders with high unmet need. This is expected to drive their uptake over the forecast period.
PEST Analysis
Political: Government regulations regarding RNA therapeutics clinical trial approvals and funding support for research and development.
Economic: Changes in economic conditions that affect healthcare spending and demand for RNA therapeutics to treat various diseases.
Social: Growing awareness and acceptance of RNA therapeutics as a treatment alternative, changing lifestyle and dietary patterns affecting disease incidence.
Technological: Advancements in RNA engineering and delivery technologies enabling development of RNA therapeutics for new therapeutic areas and improving their stability, efficacy and safety profiles. Developments in gene sequencing and bioinformatics are also supporting RNA therapeutic drug design and development.
North America currently generates the highest demand for RNA therapeutics, primarily driven by high healthcare expenditure, presence of advanced healthcare infrastructure and growing R&D initiatives. The United States alone accounts for over 50% of the RNA Therapeutics Market value owing to presence of major pharmaceutical companies and biotechs actively conducting clinical trials.
The Asia Pacific region is expected to exhibit fastest growth during the forecast period supported by rising healthcare spending, expanding population with high disease burden, increasing collaborations between local and global players. China and India are emerging as lucrative markets with presence of contract manufacturing and growing clinical trial activities.
What Are The Key Data Covered In This RNA Therapeutics Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the RNA Therapeutics’s growth between 2024 and 2031.
:- Accurate calculation of the size of the RNA Therapeutics and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- RNA Therapeutics Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of RNA Therapeutics vendors
FAQ’s
Q.1 What are the main factors influencing the RNA Therapeutics?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top RNA Therapeutics companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the RNA Therapeutics’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Alice Mutum
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights. LinkedIn
